B. Riley Securities Reiterates Buy on Fusion Pharmaceuticals, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Yuan Zhi has reiterated a 'Buy' rating on Fusion Pharmaceuticals (NASDAQ:FUSN) and maintained a price target of $13.
October 03, 2023 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fusion Pharmaceuticals has received a reiterated 'Buy' rating from B. Riley Securities, with a maintained price target of $13.
The reiterated 'Buy' rating and maintained price target by B. Riley Securities indicates a positive outlook for Fusion Pharmaceuticals. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100